Fresenius Medical Care North America has invested in BioIntelliSense, a company developing a remote, continuous health monitoring data platform.
The platform provides predictive analytics, clinical insights and real-time data through medical-grade sensors. Fresenius Medical Care North America (FMCNA) completed the investment to improve monitoring, treatment and outcomes for patients with kidney disease, the company said in a press release.
“These innovations may help more patients feel confident about trying home dialysis by staying well connected to their caregivers, and will also help advance our leading position in providing value based care for chronic diseases,” Frank Maddux, MD, global chief medical officer of FMC, said in the release.
Fresenius said it will use its experience with analytics and artificial intelligence to advance the platform and assist BioIntelliSense in the development of clinical pathways that could avoid hospitalization by alerting clinicians of the need for early intervention.
“We are committed to helping more people living with chronic kidney disease through earlier interventions and are proud to invest in a company that is leading innovation in remote health sensors and services that we believe will help us accelerate change, further improve quality care and slow progression of chronic kidney disease,” Bill Valle, CEO of FMCNA, said.